免疫检查点抑制剂治疗后骨折率增加:一种潜在的新型免疫相关不良事件
基于阿尔伯塔癌症登记数据,纳入2010年9月29日至2019年3月31日期间接受ICI治疗的1600例癌症患者,比较ICI启动前后骨折率。ICI启动后第一年骨折率显著高于启动前一年(27.3 vs 11.3/1000人年),发生率比为2.43(95%CI 1.34-4.27),作者认为骨折风险可能在ICI启动后早期增加,或为新型免疫相关不良事件。
要点
- ICI启动后第一年骨折率为27.3/1000人年,显著高于启动前一年的11.3/1000人年。
- ICI启动后第一年发生主要骨折的发生率比为2.43(95%CI 1.34-4.27)。
- 作者认为骨折风险可能在ICI启动后早期增加,或代表新型免疫相关不良事件。
核心结论
- 作者认为癌症患者在ICI启动后早期骨折风险可能增加,这可能代表一种新型免疫相关不良事件。
研究设计与样本
- 利用阿尔伯塔癌症登记数据,识别2010年9月29日至2019年3月31日期间因癌症接受ICI治疗的所有个体。
- 链接阿尔伯塔省医疗行政数据库,评估ICI启动前一年至启动后最多两年内骨折诊断代码的出现情况。
- 研究队列共1600例ICI使用者,平均年龄65.7岁,60%为男性。
主要发现
- 多数患者接受抗PD-1药物治疗(73.9%)。
- ICI在癌症诊断后平均707.8天启动。
- 76例(4.8%)有主要骨折的远期病史,141例(8.8%)在ICI治疗前曾接受骨质疏松药物治疗。
- ICI启动前一年骨折率为11.3/1000人年,启动后第一年骨折率显著更高为27.3/1000人年,启动后第二年降至17.6/1000人年。
- ICI启动后第一年相比启动前一年发生主要骨折的发生率比为2.43(95%CI 1.34-4.27)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: T cell activation can lead to osteoporosis and while there are several case reports of fractures occurring after immune checkpoint inhibitor (ICI) use, to date, there are no population level studies looking at fracture risk related to ICI use. METHODS: Using Alberta Cancer Registry data, we identified all individuals treated with ICI for cancer between September 29, 2010, and March 31, 2019. Linked records from Alberta's healthcare administrative databases were assessed for the presence of fracture diagnostic codes in the year prior to and up to two years after ICI initiation. Fracture rate was stratified based on the time-period before and after ICI initiation. Fracture rates after ICI were compared to baseline. RESULTS: The study cohort consisted of 1600 ICI users (mean age 65.7 years, 60% male). Most patients were treated with an anti-PD-1 agent (73.9%). ICIs were initiated on average 707.8 days after cancer diagnosis. 76 (4.8%) individuals had a remote history of a major fracture, and 141 (8.8%) had been treated with an osteoporosis medication prior to ICI treatment. The fracture rate in the year prior to ICI initiation was 11.3 per 1000 patient-years. The fracture rate in the year after ICI initiation was significantly higher at 27.3 per 1000 patient-years. The fracture rate dropped to 17.6 per 1000 patient-years in the second year after ICI initiation. The incidence rate ratio of sustaining a major fracture in the year after compared to the year prior to ICI initiation was 2.43 (95% CI 1.34-4.27). CONCLUSIONS: Fracture risk may be increased in cancer patients early after initiation of ICI, and this may represent a novel immune-related adverse event.
引用
- Ye C, Lee K, Leslie WD, et al. Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event. Osteoporos Int. 2023. PMID: 36729143. doi:10.1007/s00198-023-06690-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。